Centene Corporation Third Quarter Earnings Release - CENTENE CORP

Financial Performance:

• Reported Q3 2026 adjusted diluted EPS of $0.58, beating expectations.
• Raised full-year 2026 adjusted diluted EPS guidance to greater than $5.20 (from >$4.80).
• Consolidated premium and service revenue was $45.1 billion; consolidated HBR (Health Benefit Ratio) was 92.7%, improving by 15 basis points.
• Segment-specific HBRs: Medicaid 93.6%, Medicare 93.8%.
• Adjusted SG&A expense ratio was 6.5% in Q3, down from 7.0% in Q3 2025; full-year guidance remains at a midpoint of 7.2%.
• Ended Q3 with $175 million in cash available for general corporate use; repurchased $1.1 billion in senior notes.
• Total debt reduced to $15.0 billion from $18.5 billion at end of 2024; debt-to-capital ratio is 41.1%.
• Q3 operating cash flow used was $3.7 billion (due to $3+ billion Medicaid pass-through payment); YTD operating cash flow provided was $4.3 billion.
• Expected full-year 2026 pre-tax margins: Marketplace 5.0% (top of range), PDP mid-to-high 3s, Medicare Advantage break-even.

Guidance and Future Outlook:

• 2026 financial outlook driven by Medicare segment outperformance, Marketplace margin expansion, and lower interest expenses (midpoint $610 million).
• Expect earnings growth in 2027 off an adjusted EPS base of approximately $4.70 (excluding non-recurring 2026 items).
• Medicaid HBR forecasted to improve slightly in 2027 despite OB3 headwinds; 2026 membership expected to drop 8-9% year-over-year.
• Medicare Advantage projected to move from break-even in 2026 to above break-even in 2027 following a strategic footprint reduction.
• Part D (PDP) enrollment expected to tilt toward growth in 2027; margins expected to reset to 2-3% initially before improving.
• Marketplace pre-tax margin expected to remain strong, with formal 2027 guidance to be released in February 2027.
• Full-year 2026 membership end-of-year forecast: Medicaid ~10.9 million, Marketplace ~3.2 million.

Business Segments and Product Lines:

• Medicaid: HBR at 93.6%; trend stabilization observed in behavioral health and home health; focusing on fraud, waste, and abuse interventions; executing work requirement compliance plans.
• Medicare: Strong performance in both Advantage and Part D; Advantage turnaround on track to break-even in 2026 (ahead of schedule); Part D margins improved due to scale and cost optimization.
• Marketplace (Commercial): Underlying strength allowed absorption of IDR (Independent Dispute Resolution) costs; silver tier trend moderating; Expanding product suite with tailored benefit plans for 2027.
• Product Innovation: Launched healthy food benefits in Nebraska Total Care; data-driven supplemental benefits for Medicare DSNP (groceries, housing, transportation) resulted in ~$200 per member per month lower claims for participating cohorts.
• Operational Exits: Exiting Health Net commercial group business in California over 18-24 months.

Market and Competitive Landscape:

• Medicaid rate discussions show increased engagement with states for 2027, with explicit provisions for OB3 acuity shifts in draft rates.
• CMS STARS results (42% of members at 3.5+ stars) in line with expectations despite industry headwinds; Centene outpaced industry in preventative care measures.
• Marketplace facing market contraction due to expiration of Enhanced Premium Tax Credits; managing unauthorized enrollments and broker fraud.
• Competition in Part D remains fierce; leveraging scale and direct subsidy increases to drive yield.
• State-level adoption of work requirements expected to be methodical rather than immediate, smoothing membership drops into 2028.

Risks and Challenges:

• OB3 (Unwinding of the Public Health Emergency) eligibility terminations causing 8-9% Medicaid membership attrition and potential acuity shifts.
• Work requirements implementation risks, specifically dislocation between rates and acuity if state rate-setting lags behind enrollment changes.
• Independent Dispute Resolution (IDR) costs and provider gaming of the No Surprises Act impacting commercial segment.
• Policy uncertainty regarding 1115 waivers (shift to budget neutrality) potentially curbing innovation.
• Potential mid-term election outcomes affecting state leadership and Medicaid administration continuity.
• Q4 seasonal utilization spikes typical for exchange members and commercial products.

Management Commentary and Tone:

• Tone is confident and optimistic, emphasizing disciplined execution, margin restoration, and successful cost management.
• Management highlighted "unmatched expertise" and a "mission-driven model" as competitive advantages in navigating policy changes.
• Emphasis on data-driven decision-making and innovation (e.g., food insecurity initiatives) to improve health outcomes and reduce costs.
• CEO expressed pride in the team's resilience in the face of 2025 disruptions, positioning the company for sustained growth in 2027.

Analyst Questions and Answers:

• Medicaid Rates: States are actively engaging to prospectively account for work requirement acuity; positive signals on rate adequacy using 2025 data.
• Marketplace Growth: Overall market expected to contract in 2027; Centene focusing on margin expansion over pure volume growth.
• PDP Margins: Expected to reset to 2-3% range in 2027 from 2026 outperformance, driven by normalization of Inflation Reduction Act impacts.
• G&A Efficiency: $480 million optimization savings largely booked in Q3 2026; SG&A ratio expected to remain a tailwind in 2027.
• Q4 Acuity: Q4 acuity impact held in guidance; most 8-9% membership drop and acuity shift anticipated in Q4 to align with work requirement timelines.
• Florida CMS: Slight utilization uptick in September due to transition anxiety; fully executed on 10/1 exit.
• Policy Risk: No significant disruption expected from mid-term elections due to federal frameworks and strong state agency relationships.

Other Key Points:

• Centene's "SEND team" (Social and Environmental Needs Determinants) is delivering measurable health outcome improvements via food and housing benefits.
• The company is advocating for STARS reforms to better support vulnerable populations.
• 2026 guidance includes $0.50 non-recurring earnings not expected in 2027.
• 2027 outlook relies on continued rate trend stabilization in Medicaid and margin expansion in Commercial/Medicare.
• Total debt reduction and interest expense savings are key financial enablers for 2026 performance.